Companies
Johnson & Johnson jumps after arthritis pill meets trial goal
Johnson & Johnson shares jumped 2.1% to a 52-week high after late-stage data showed its arthritis pill Icotyde beat a placebo, on a day the broad market rallied.
Quick Read
- Johnson & Johnson shares jumped 2.1% Monday to close at a 52-week high.
- Late-stage data presented Saturday showed more patients on Icotyde, an oral psoriatic arthritis drug, reached a joint-improvement mark than on placebo, with no new safety signals, the company said.
- The broad market rallied too, and the S&P 500 rose slightly more than J&J did.
How much did Johnson & Johnson stock rise?
Johnson & Johnson (NYSE: JNJ) shares jumped 2.1% on Monday, from $276.22 to a close of $282.11. That is a 52-week high, the highest price in the past year.
Why it matters: The gain added $14 billion to the company's stock market value, which ended the day at $680 billion. Someone who put $1,000 into the shares a year ago held $1,512 at Monday's close.
What did the Icotyde trial show?
On Saturday, J&J presented late-stage results for Icotyde, a pill for psoriatic arthritis, at the ACR Convergence 2026 meeting of the American College of Rheumatology. Psoriatic arthritis is an inflammatory disease that causes painful, swollen joints.
The study enrolled adults who had not yet tried biologics, the injected drugs made from living cells. It met its primary endpoint, the main goal the study was built to test.
About 58% of patients on the drug reached a standard joint-improvement mark, against 41% on placebo, the company said. Stronger responses and clearer skin were also more common on the drug, and results kept improving with longer treatment. J&J reported no new safety signals.
The company also shared patient-experience data for nipocalimab, a drug for Sjögren's disease, an immune illness that causes dry mouth. J&J said it has started a late-stage trial of that drug.
Was the trial the only reason the stock rose?
Not entirely. The S&P 500 jumped 2.3% on Monday, slightly more than J&J. The health care sector fund (XLV) rose 1.9%, a bit less than J&J. In all, 958 of 1,112 stocks rose.
That leaves an open question: how much of J&J's gain came from Icotyde, and how much from a day when most stocks climbed.
J&J accounts for 0.76% of the value of the 500 largest U.S. companies, so its gain added $16 to $100,000 spread across them by size.
What comes next?
What’s next: The next scheduled event is market-wide: the October consumer price index, the monthly inflation report, at 8:30 a.m. ET on Tuesday, Nov. 10. It could shape the broad rally that lifted J&J along with most other stocks.
For readers
What it could mean for you: If you own J&J shares directly, Monday's move landed in full, with no other holdings to offset it. The stock now sits at its highest price in a year, lifted partly by Icotyde's trial results and partly by a market-wide rally. Further results for Icotyde, or news from the late-stage nipocalimab trial, could move the shares again in either direction. A broad market swing, like the one the October inflation report might bring, could matter as much as the drug news.
Questions and answers
Why did Johnson & Johnson stock go up?
J&J presented late-stage trial results on Saturday showing its psoriatic arthritis pill Icotyde beat a placebo. The shares also rose on a day when the S&P 500 and most stocks climbed.
What is Icotyde and what does it treat?
Icotyde is a pill J&J is testing for psoriatic arthritis, an inflammatory disease that causes painful, swollen joints. The latest study enrolled adults who had not yet tried injected biologic drugs.
What did the Icotyde trial show?
About 58% of patients on the drug reached a standard joint-improvement mark, against 41% on placebo, the company said. J&J reported no new safety signals.
The numbers
| Johnson & Johnson (JNJ) price | $282.11 |
|---|---|
| Johnson & Johnson (JNJ) change | +2.13% |
| Johnson & Johnson (JNJ) market value | $680 billion |
| Johnson & Johnson (JNJ) 52-week high | $282.11 |
| S&P 500 change | +2.35% |
| 10-year Treasury yield | 4.88% |
Monday’s close
Companies in this story
Share this story
Not investment advice.
